Pfizer/$PFE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Ticker
$PFE
Sector
Primary listing
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
81,000
ISIN
US7170811035
Website
Pfizer Metrics
BasicAdvanced
$138B
17.52
$1.38
0.49
$1.70
7.10%
Price and volume
Market cap
$138B
Beta
0.49
52-week high
$31.54
52-week low
$20.92
Average daily volume
39M
Dividend rate
$1.70
Financial strength
Current ratio
1.258
Quick ratio
0.88
Long term debt to equity
63.9
Total debt to equity
76.181
Dividend payout ratio (TTM)
121.49%
Interest coverage (TTM)
5.57%
Profitability
EBITDA (TTM)
23,506.5
Gross margin (TTM)
74.42%
Net profit margin (TTM)
12.62%
Operating margin (TTM)
26.41%
Effective tax rate (TTM)
-6.90%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
4.79%
Return on equity (TTM)
8.62%
Valuation
Price to earnings (TTM)
17.524
Price to revenue (TTM)
2.2
Price to book
1.53
Price to tangible book (TTM)
-3.84
Price to free cash flow (TTM)
12.246
Free cash flow yield (TTM)
8.17%
Free cash flow per share (TTM)
197.94%
Dividend yield (TTM)
7.01%
Forward dividend yield
7.10%
Growth
Revenue change (TTM)
11.65%
Earnings per share change (TTM)
-2,464.07%
3-year revenue growth (CAGR)
-12.25%
10-year revenue growth (CAGR)
2.43%
3-year earnings per share growth (CAGR)
-31.81%
10-year earnings per share growth (CAGR)
-0.41%
3-year dividend per share growth (CAGR)
2.49%
10-year dividend per share growth (CAGR)
4.78%
What the Analysts think about Pfizer
Analyst ratings (Buy, Hold, Sell) for Pfizer stock.
Bulls say / Bears say
Pfizer's cost-cutting measures have led to better-than-expected fourth-quarter profits, with total revenue reaching $17.8 billion, exceeding analysts' estimates. (reuters.com)
The acquisition of cancer drugmaker Seagen has contributed to revenue growth, with Padcev sales reaching $444 million, indicating a strengthening oncology portfolio. (reuters.com)
Pfizer's partnership with 3SBio aims to penetrate the Chinese biopharmaceutical market, leveraging local expertise to fast-track product approvals and gain a competitive edge. (pandaforecast.com)
Pfizer reported lower-than-expected revenue for the first quarter of 2025, primarily due to decreased sales of its COVID-19 treatment, Paxlovid, which fell to $491 million, significantly below analysts’ estimates. (reuters.com)
Institutional Shareholder Services (ISS) advised Pfizer shareholders to reject an executive compensation proposal, citing concerns over changes to long-term awards and lack of transparency, which could undermine investor confidence. (reuters.com)
A smaller wave of U.S. COVID-19 cases this winter has led to decreased demand for Pfizer's COVID-related products, adding pressure on the company to find growth from its non-COVID treatments. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 22 Jun 2025.
Pfizer Financial Performance
Revenues and expenses
Pfizer Earnings Performance
Company profitability
Pfizer News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul25
Pfizer
Dividend·Ex-dividend
Sept2
Pfizer
Dividend·Payment
$0.43Per share
FAQs
What’s the current market cap for Pfizer stock?
Pfizer (PFE) has a market cap of $138B as of June 27, 2025.
What is the P/E ratio for Pfizer stock?
The price to earnings (P/E) ratio for Pfizer (PFE) stock is 17.52 as of June 27, 2025.
Does Pfizer stock pay dividends?
Yes, the Pfizer (PFE) stock pays dividends to shareholders. As of June 27, 2025, the dividend rate is $1.7 and the yield is 7.1%. Pfizer has a payout ratio of 121.49% on a trailing twelve-month basis.
When is the next Pfizer dividend payment date?
The next Pfizer (PFE) dividend payment is scheduled for September 02, 2025.
What is the beta indicator for Pfizer?
Pfizer (PFE) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.